ArticleBMC neurology2026
Association of high-sensitivity C-reactive protein-triglyceride glucose index and stroke outcomes: results from the China National Stroke Registry III.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe high-sensitivity C-reactive protein-triglyceride glucose index (hsCTI) is an integrated biomarker reflecting systemic inflammation and insulin resistance. This study aimed to evaluate the association between hsCTI levels and the risk of stroke recurrence in a large, real-world cohort.
methodsWe analyzed data from the China National Stroke Registry-III, including patients with acute ischemic stroke or transient ischemic attack (TIA). The hsCTI was calculated as 0.412 × ln(hsCRP [mg/L]) + ln(TG [mg/dL] × FPG [mg/dL]/2). Outcomes included stroke recurrence, ischemic stroke recurrence, and composite vascular events. Kaplan-Meier curves and Cox proportional hazards models were employed to evaluate the association between hsCTI and clinical outcomes, stratified by sex, age, and glycemic status. The area under the curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were calculated to evaluate the incremental risk prediction capabilities of hsCTI and TyG index beyond traditional risk factors.
resultsAmong 4,969 included patients (67.8% male), those in the highest hsCTI quartile (Q4) experienced increased risks of recurrent stroke and composite vascular events during a maximum follow-up of 5 years. Compared with the lowest quartile, Q4 was associated with significantly elevated 3-month stroke recurrence (adjusted hazard ratio [aHR], 1.83; 95% CI, 1.23-2.73) and composite vascular events (aHR, 2.04; 95% CI, 1.38-3.00), with associations remaining significant at 1 year. The prognostic value was most pronounced in individuals aged ≥ 60 years. Subgroup analyses identified significant interactions between hsCTI and age (P for interaction = 0.009), as well as National Institutes of Health Stroke Scale (NIHSS) score at admission (P for interaction = 0.017). Adding hsCTI to the reference model significantly improved clinical risk prediction (all P < 0.001for NRI and IDI).
conclusionsElevated baseline hsCTI level was associated with an increased risk of stroke recurrence and composite vascular events. HsCTI may serve as a potential biomarker for identifying residual vascular risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.